https://www.aceso-therapeutics.com/publication/cftr-restoration-strategies-in-difficult-to-treat-mutation-classes-%c2%b7-journal-name/2026-05-21T13:18:46+00:00https://www.aceso-therapeutics.com/publication/dual-mechanism-therapeutic-approaches-for-cystic-fibrosis-%c2%b7-journal-name/2026-05-21T13:19:15+00:00https://www.aceso-therapeutics.com/publication/addressing-underserved-cf-populations-through-targeted-rescue-pathways-%c2%b7-journal-name/2026-05-21T13:19:44+00:00https://www.aceso-therapeutics.com/publication/translational-frameworks-for-next-generation-cftr-therapies-%c2%b7-journal-name/2026-05-21T13:20:13+00:00https://www.aceso-therapeutics.com/publication/transcription-factors-mirnas-that-regulate-fetal-to-adult-cftr-expression-change-are-new-targets-for-cf-treatment/2026-06-09T05:39:45+00:00https://www.aceso-therapeutics.com/publication/mirna-repertoires-of-cystic-fibrosis-ex-vivo-models-highlight-mir-181a-and-mir-101-that-regulate-wisp1-expression/2026-05-28T21:14:39+00:00https://www.aceso-therapeutics.com/publication/splicing-mutations-in-the-cftr-gene-as-therapeutic-targets/2026-05-28T21:14:48+00:00https://www.aceso-therapeutics.com/publication/ecfs-2025-cftr-stabilizers-as-therapeutic-tools-in-cystic-fibrosis/2026-05-28T21:14:07+00:00https://www.aceso-therapeutics.com/publication/ecfs-eyim-2026-optimization-of-blocker-oligonucleotides-as-therapies-to-correct-consequences-of-deep-intronic-mutations/2026-05-28T21:14:01+00:00